197 related articles for article (PubMed ID: 35959380)
1. A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
Chung C
Blood Lymphat Cancer; 2022; 12():99-106. PubMed ID: 35959380
[TBL] [Abstract][Full Text] [Related]
2. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Julia E; Salles G
Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
[TBL] [Abstract][Full Text] [Related]
3. Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat.
Raychaudhuri R; Ujjani C
Onco Targets Ther; 2022; 15():193-199. PubMed ID: 35250278
[TBL] [Abstract][Full Text] [Related]
4. Treating lymphoma is now a bit EZ-er.
Morin RD; Arthur SE; Assouline S
Blood Adv; 2021 Apr; 5(8):2256-2263. PubMed ID: 33904892
[TBL] [Abstract][Full Text] [Related]
5. The role of tazemetostat in relapsed/refractory follicular lymphoma.
von Keudell G; Salles G
Ther Adv Hematol; 2021; 12():20406207211015882. PubMed ID: 34104370
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
Munakata W; Shirasugi Y; Tobinai K; Onizuka M; Makita S; Suzuki R; Maruyama D; Kawai H; Izutsu K; Nakanishi T; Shiba S; Hojo S; Ando K
Cancer Sci; 2021 Mar; 112(3):1123-1131. PubMed ID: 33492746
[TBL] [Abstract][Full Text] [Related]
7. Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma.
Mondello P; Ansell SM
Expert Opin Pharmacother; 2022 Feb; 23(3):295-301. PubMed ID: 34904909
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.
Serganova I; Chakraborty S; Yamshon S; Isshiki Y; Bucktrout R; Melnick A; Béguelin W; Zappasodi R
Front Cell Dev Biol; 2021; 9():805195. PubMed ID: 35071240
[TBL] [Abstract][Full Text] [Related]
9. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
[TBL] [Abstract][Full Text] [Related]
11. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Morschhauser F; Tilly H; Chaidos A; McKay P; Phillips T; Assouline S; Batlevi CL; Campbell P; Ribrag V; Damaj GL; Dickinson M; Jurczak W; Kazmierczak M; Opat S; Radford J; Schmitt A; Yang J; Whalen J; Agarwal S; Adib D; Salles G
Lancet Oncol; 2020 Nov; 21(11):1433-1442. PubMed ID: 33035457
[TBL] [Abstract][Full Text] [Related]
12. Tazemetostat: EZH2 Inhibitor.
Straining R; Eighmy W
J Adv Pract Oncol; 2022 Mar; 13(2):158-163. PubMed ID: 35369397
[TBL] [Abstract][Full Text] [Related]
13. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
[TBL] [Abstract][Full Text] [Related]
14. Hypomethylating Agents in Lymphoma.
Cogan JC; Liu Y; Amengual JE
Curr Treat Options Oncol; 2020 Jun; 21(8):61. PubMed ID: 32601883
[TBL] [Abstract][Full Text] [Related]
15. [Epigenetic modification as a therapeutic approach for B-cell lymphoma].
Nishikori M; Takaori-Kondo A
Rinsho Ketsueki; 2022; 63(4):313-321. PubMed ID: 35491222
[TBL] [Abstract][Full Text] [Related]
16. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK
Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772
[TBL] [Abstract][Full Text] [Related]
17. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
18. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
19. Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.
Lunning MA; Green MR
Blood Cancer J; 2015 Oct; 5(10):e361. PubMed ID: 26473533
[TBL] [Abstract][Full Text] [Related]
20. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
